Professor Gerald Holtmann
Professor

Gerald Holtmann

Email: 

Background

Prof Holtmann is a Clinical Academic in the field of Gastroenterology & Hepatology and Director of Clinical Innovation. He is also Director of the Department of Gastroenterology & Hepatology at the Princess Alexandra Hospital in Queensland and serves on the Board of Directors of the West Moreton Hospital and Health Service and UQ Healthcare. He is a Fellow of Royal Australian Collge of Physicians (RACP, Sydney), the Royal College of Physicians (RCP, London) and Fellow of the Australian Academy of Health and Medical Sciences (AAHMS, Canberra). Besides his Medical Qualifications he also obtained a Master of Business Administration. After completing the clinical training in Medicine and Gastroenterology at the University of Essen in Germany and the Mayo Clinic in Rochester, Minnesota in the United States, he has gained substantial leadership and managerial experience within the health care setting as Director of large Gastroenterology Departments, CEO and General Manager of a University Hospital and Health Care Facilities and has served on the Board of the University Hospital Essen in Germany. His research is in the field of Neurogastroenterology has resulted in peer reviewed publications in key journal including the NEJM, Lancet, Gastroenterology and Gut. More recently his rersearch focus is on the role of the gut microbiome, mucosal and systemic inflammation and brain-gut interactions.

Availability

Professor Gerald Holtmann is:
Available for supervision
Media expert

Search Professor Gerald Holtmann’s works on UQ eSpace

556 works between 1986 and 2026
All (556) Journal Article (413) Conference Publication (139) Book Chapter (4)

1 - 20 of 556 works

2026

Journal Article

Gastrointestinal Symptoms and Systemic Comorbidities in Patients With <scp>POTS</scp> : A Systematic Review and Meta‐Analysis

Kulin, Dmitrii, Shah, Ayesha, Fairlie, Thomas, Staller, Kyle, Nurko, Samuel, Keefer, Laurie, Aziz, Qasim, Drossman, Douglas A., Jones, Michael P. and Holtmann, Gerald (2026). Gastrointestinal Symptoms and Systemic Comorbidities in Patients With POTS : A Systematic Review and Meta‐Analysis. Neurogastroenterology & Motility, 38 (4) e70305. doi: 10.1111/nmo.70305

Gastrointestinal Symptoms and Systemic Comorbidities in Patients With <scp>POTS</scp> : A Systematic Review and Meta‐Analysis

2026

Journal Article

Ready for Prime Time? Breath Testing to Diagnose Intestinal Dysbiosis and Guide Management in Patients With Functional Defecation Disorders

Shah, Ayesha and Holtmann, Gerald (2026). Ready for Prime Time? Breath Testing to Diagnose Intestinal Dysbiosis and Guide Management in Patients With Functional Defecation Disorders. Neurogastroenterology and Motility, 38 (4) e70275. doi: 10.1111/nmo.70275

Ready for Prime Time? Breath Testing to Diagnose Intestinal Dysbiosis and Guide Management in Patients With Functional Defecation Disorders

2026

Journal Article

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Long, Millie, Allegretti, Jessica R, Danese, Silvio, Germinaro, Matthew, Baker, Thomas, Alvarez, Yelina, Kavalam, Mary, Han, Chenglong, Jörgens, Silke, Jiang, Lingjing, Zhang, Hongyan, Hisamatsu, Tadakazu, Rubin, David T, Peyrin-Biroulet, Laurent, Abu-Farsakh, Niazy, Al-Rousan, Lawrence, An, Ping, Argollo, Marjorie, Arguelles Arias, Federico, Augustyn, Monika, Baert, Filip, Balderramo, Domingo, Banerjee, Rupa, Baum, Curtis, Bermudez Villegas, Emilio, Blanco, Antonio, Bortlik, Martin, Bouhnik, Yoram, Soledad Brunatto, Luciana ... Zou, Duowu (2026). Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. The Lancet Gastroenterology and Hepatology, 11 (4), 284-298. doi: 10.1016/S2468-1253(25)00322-X

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

2026

Journal Article

symptom patterns outside the rome iv consensus in eastern and western patients with a disorder of gut-brain interaction

Colomier, Esther, Jones, Michael P., Holvoet, Lieselot, Van den Houte, Karen, Van de Bruaene, Cedric, Broeders, Bert, Bai, Tao, Liu, Jinsong, Melchior, Chloé, Gourcerol, Guillaume, Chuah, Kee-Huat, Hui, Khoo Xin, Mahadeva, Sanjiv, Ho Siah, Kewin Tien, Lipták, Peter, Banovcin, Peter, Holtmann, Gerald, Koloski, Natasha, Carabotti, Marilia, Annibale, Bruno, Suzuki, Hidekazu, Sano, Masaya, Ueda, Takashi, Hajihashemi, Parisa, Shahoon, Hassan, Adibi, Payman, Simrén, Magnus, Gwee, Kok-Ann, Tack, Jan and Carbone, Florencia (2026). symptom patterns outside the rome iv consensus in eastern and western patients with a disorder of gut-brain interaction. American Journal of Gastroenterology, Publish Ahead of Print 10.14309/ajg.0000000000003996. doi: 10.14309/ajg.0000000000003996

symptom patterns outside the rome iv consensus in eastern and western patients with a disorder of gut-brain interaction

2026

Conference Publication

WEIGHT LOSS OUTCOMES IN RESPONSE TO TREATMENT WITH DUODENAL-JEJUNAL BYPASS LINER ARE THE SAME REGARDLESS OF DIABETES SEVERITY ASSESSED USING THE INDIVIDUALIZED METABOLIC SURGERY SCORE

Idris, Iskandar, Benes, Marek, Haluzik, Martin, Byrne, James, Munro, Lynne, Frydenberg, Harry, Teare, Julian, Ruban, Aruchuna, Mason, John, Holtmann, Gerald, Mcmaster, Jess and Ryder, Robert (2026). WEIGHT LOSS OUTCOMES IN RESPONSE TO TREATMENT WITH DUODENAL-JEJUNAL BYPASS LINER ARE THE SAME REGARDLESS OF DIABETES SEVERITY ASSESSED USING THE INDIVIDUALIZED METABOLIC SURGERY SCORE. THOUSAND OAKS: SAGE PUBLICATIONS INC.

WEIGHT LOSS OUTCOMES IN RESPONSE TO TREATMENT WITH DUODENAL-JEJUNAL BYPASS LINER ARE THE SAME REGARDLESS OF DIABETES SEVERITY ASSESSED USING THE INDIVIDUALIZED METABOLIC SURGERY SCORE

2026

Journal Article

Measuring lifetime alcohol exposure: A scoping review and implications for translational research and alcohol‐related harm

Palmer, Andrew J., Connor, Jason P., Holtmann, Gerald, Saunders, John B., Rice, Katie, Yeo, Jeremy, Huang, Andrea and Clark, Paul J. (2026). Measuring lifetime alcohol exposure: A scoping review and implications for translational research and alcohol‐related harm. Addiction, 121 (3), 472-487. doi: 10.1111/add.70208

Measuring lifetime alcohol exposure: A scoping review and implications for translational research and alcohol‐related harm

2026

Journal Article

Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease – paving a path forward

Grady, John, Johnson, Kevin M., Kellermayer, Richard, Winter, Harland S., Tabibian, James H., Buness, Cynthia W., Fischer, Ryan, Shah, Ayesha, Dulai, Parambir S., Rangnekar, Amol S., Alrabadi, Leina, Shah, Shamita B., Holtmann, Gerald, Räisänen, Laura, Lewindon, Peter and Ali, Ahmad H. (2026). Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease – paving a path forward. Expert Review of Gastroenterology & Hepatology, 20 (3) 17474124.2026.2635420, 233-246. doi: 10.1080/17474124.2026.2635420

Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease – paving a path forward

2026

Journal Article

Sociocultural Aspects of the Pathophysiology, Clinical Presentation and Management of Disorders of Gut-Brain Interaction

Wong, Reuben K., Fang, Xiucai, Ghoshal, Uday C., Kashyap, Purna C., Mulak, Agata, Lee, Yeong Yeh, Sperber, Ami D. and Holtmann, Gerald (2026). Sociocultural Aspects of the Pathophysiology, Clinical Presentation and Management of Disorders of Gut-Brain Interaction. Gastroenterology, 170 (6), 1190-1204. doi: 10.1053/j.gastro.2026.02.006

Sociocultural Aspects of the Pathophysiology, Clinical Presentation and Management of Disorders of Gut-Brain Interaction

2026

Journal Article

Disorders of gut–brain interaction (DGBI) symptoms and response to peroral endoscopic myotomy in patients with achalasia

Jacob, Ronen Ben, Fairlie, Thomas, Talley, Nicholas J., Taylor, Andrew, Frankel, Adam, Smithers, B. Mark, Pandolfino, John E., Jones, Michael P., Hourigan, Luke F., Shah, Ayesha and Holtmann, Gerald (2026). Disorders of gut–brain interaction (DGBI) symptoms and response to peroral endoscopic myotomy in patients with achalasia. Neurogastroenterology and Motility, 38 (1) e70223, 1-11. doi: 10.1111/nmo.70223

Disorders of gut–brain interaction (DGBI) symptoms and response to peroral endoscopic myotomy in patients with achalasia

2025

Journal Article

Evidence for brain‐to‐gut and gut‐to‐brain pathways in primary care patients with disorders of gut‐brain interaction, inflammatory bowel disease and gastroesophageal reflux disease

Koloski, N. A., Jones, M. P., Shah, A., Holtmann, G. and Talley, N. J. (2025). Evidence for brain‐to‐gut and gut‐to‐brain pathways in primary care patients with disorders of gut‐brain interaction, inflammatory bowel disease and gastroesophageal reflux disease. Neurogastroenterology and Motility, 37 (12) e70117, e70117. doi: 10.1111/nmo.70117

Evidence for brain‐to‐gut and gut‐to‐brain pathways in primary care patients with disorders of gut‐brain interaction, inflammatory bowel disease and gastroesophageal reflux disease

2025

Journal Article

Key recommendations to improve equity and access in colorectal cancer screening for rural and remote communities. a grounded theory study

Marinucci, Nicole, Koloski, Natasha, Baker, Kate, Moy, Naomi and Holtmann, Gerald (2025). Key recommendations to improve equity and access in colorectal cancer screening for rural and remote communities. a grounded theory study. Australian and New Zealand Journal of Public Health, 49 (6) 100295, 100295. doi: 10.1016/j.anzjph.2025.100295

Key recommendations to improve equity and access in colorectal cancer screening for rural and remote communities. a grounded theory study

2025

Conference Publication

Results From Dose Escalation Cohorts 1-6 of RESOLVE, an Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) for Eosinophilic Esophagitis

Malone, Amanda, Helliwell, James, Kowalski, Mark, Nguyen, Nam, Ko, Hin Hin, Holtmann, Gerald, Afif, Waqqas, Bredenoord, Albert J., Dobek, Christine, Ravikumar, Pranali, Peck, Vik and Dellon, Evan S. (2025). Results From Dose Escalation Cohorts 1-6 of RESOLVE, an Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) for Eosinophilic Esophagitis. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.14309/01.ajg.0001131024.83021.f2

Results From Dose Escalation Cohorts 1-6 of RESOLVE, an Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) for Eosinophilic Esophagitis

2025

Journal Article

Immune Activation in Primary Sclerosing Cholangitis: A Systematic Review and Comparative Analysis With Inflammatory Bowel Diseases

Moniruzzaman, Md, Shah, Ayesha, Fairlie, Thomas, Keely, Simon, Burns, Grace L., Talley, Nicholas and Holtmann, Gerald (2025). Immune Activation in Primary Sclerosing Cholangitis: A Systematic Review and Comparative Analysis With Inflammatory Bowel Diseases. United European Gastroenterology Journal, 13 (9) ueg2.70115, 1-14. doi: 10.1002/ueg2.70115

Immune Activation in Primary Sclerosing Cholangitis: A Systematic Review and Comparative Analysis With Inflammatory Bowel Diseases

2025

Conference Publication

Updated dose escalation results from RESOLVE, an ongoing Phase 1b/2a study of EP-104GI (long-acting fluticasone propionate injectable suspension) for eosinophilic esophagitis

Malone, Amanda, Helliwell, James, Kowalski, Mark M., Ko, Hin Hin, Holtmann, Gerald, Afif, Waqqas, Bredenoord, Albert J., Dellon, Evan S., Dobek, Christine, Ravikumar, Pranali, Peck, Vik and Nguyen, Nam (2025). Updated dose escalation results from RESOLVE, an ongoing Phase 1b/2a study of EP-104GI (long-acting fluticasone propionate injectable suspension) for eosinophilic esophagitis. HOBOKEN: WILEY.

Updated dose escalation results from RESOLVE, an ongoing Phase 1b/2a study of EP-104GI (long-acting fluticasone propionate injectable suspension) for eosinophilic esophagitis

2025

Journal Article

Randomized, placebo‐controlled, double‐blind 8‐week trial on the efficacy of a proprietary kiwifruit extract on constipation‐predominant irritable bowel syndrome

Holtmann, Gerald, Talley, Nicholas J., Nandurkar, Sanjay and Gibson, Peter R. (2025). Randomized, placebo‐controlled, double‐blind 8‐week trial on the efficacy of a proprietary kiwifruit extract on constipation‐predominant irritable bowel syndrome. JGH Open, 9 (8) e70250, e70250. doi: 10.1002/jgh3.70250

Randomized, placebo‐controlled, double‐blind 8‐week trial on the efficacy of a proprietary kiwifruit extract on constipation‐predominant irritable bowel syndrome

2025

Journal Article

Investigating participation in the Australian National Bowel Cancer Screening Program through general practice: a survey on practices, challenges and digital opportunities

Marinucci, Nicole, Koloski, Natasha, Whaley, Amanda, Bagnall, Rachael, Shah, Ayesha, Goodwin, Belinda and Holtmann, Gerald (2025). Investigating participation in the Australian National Bowel Cancer Screening Program through general practice: a survey on practices, challenges and digital opportunities. Public Health Research and Practice, 35 (3) PU24017, 1-8. doi: 10.1071/pu24017

Investigating participation in the Australian National Bowel Cancer Screening Program through general practice: a survey on practices, challenges and digital opportunities

2025

Journal Article

Mechanisms of action and clinical effectiveness of herbal treatments for disorders of gut-brain interaction

Moniruzzaman, Md, Shah, Ayesha, Morrison, Mark, Koloski, Natasha, Gwee, Kok Ann, Chen, Minhu, Kim, YongSung, Ayaki, Kana, Efferth, Thomas and Holtmann, Gerald (2025). Mechanisms of action and clinical effectiveness of herbal treatments for disorders of gut-brain interaction. Digestive and Liver Disease, 57 (9), 1717-1729. doi: 10.1016/j.dld.2025.07.010

Mechanisms of action and clinical effectiveness of herbal treatments for disorders of gut-brain interaction

2025

Journal Article

Navigating the maze of functional dyspepsia: emergence of a new entity, postprandial epigastric pain syndrome

Van de Bruaene, Cedric, Carbone, Florencia, Van den Houte, Karen, Colomier, Esther, Raymenants, Karlien, Broeders, Bert, Balsiger, Lukas M., Jones, Mike P., Simrén, Magnus, Bai, Tao, Liu, Jinsong, Melchior, Chloé, Gourcerol, Guillaume, Chuah, Kee-Huat, Hui, Khoo Xin, Mahadeva, Sanjiv, Siah, Kewin Tien Ho, Gwee, Kok-Ann, Lipták, Peter, Banovcin, Peter, Holtmann, Gerald, Koloski, Natasha, Carabotti, Marilia, Annibale, Bruno, Suzuki, Hidekazu, Sano, Masaya, Ueda, Takashi, Shahoon, Hassan, Adibi, Peyman ... Tack, Jan (2025). Navigating the maze of functional dyspepsia: emergence of a new entity, postprandial epigastric pain syndrome. Clinical Gastroenterology and Hepatology, 23 (13), 2607-2615. doi: 10.1016/j.cgh.2025.05.017

Navigating the maze of functional dyspepsia: emergence of a new entity, postprandial epigastric pain syndrome

2025

Journal Article

Comparison of the prevalence of meal‐related nausea in different functional dyspepsia subgroups

Broeders, Bert, Colomier, Esther, Carbone, Florencia, Simrén, Magnus, Bai, Tao, Liu, Jinsong, Melchior, Chloé, Gourcerol, Guillaume, Chuah, Kee‐Huat, Hui, Khoo Xin, Mahadeva, Sanjiv, Siah, Kewin Tien Ho, Gwee, Kok‐Ann, Lipták, Peter, Banovcin, Peter, Holtmann, Gerald, Koloski, Natasha, Carabotti, Marilia, Annibale, Bruno, Suzuki, Hidekazu, Sano, Masaya, Ueda, Takashi, Shahoon, Hassan, Adibi, Peyman, Van de Bruaene, Cedric, Vanuytsel, Tim and Tack, Jan (2025). Comparison of the prevalence of meal‐related nausea in different functional dyspepsia subgroups. Neurogastroenterology & Motility, 38 (4) e70078, 1-8. doi: 10.1111/nmo.70078

Comparison of the prevalence of meal‐related nausea in different functional dyspepsia subgroups

2025

Conference Publication

Two-thirds Of Female Patients With A Disorder Of Gut-brain Interaction And Endometriosis In Primary Care Are Diagnosed With The Gut Disorder First, And There Is A Long Delay In Finally Diagnosing Endometriosis

Koloski, Natasha A., Jones, Michael P., Shah, Ayesha, Holtmann, Gerald and Talley, Nicholas J. (2025). Two-thirds Of Female Patients With A Disorder Of Gut-brain Interaction And Endometriosis In Primary Care Are Diagnosed With The Gut Disorder First, And There Is A Long Delay In Finally Diagnosing Endometriosis. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)02854-9

Two-thirds Of Female Patients With A Disorder Of Gut-brain Interaction And Endometriosis In Primary Care Are Diagnosed With The Gut Disorder First, And There Is A Long Delay In Finally Diagnosing Endometriosis

Current funding

  • 2022 - 2026
    ARC Training Centre for Behavioural Insights for Technology Adoption (BITA) (ARC Industrial Transformation Training Centre Administered by QUT)
    Queensland University of Technology
    Open grant

Past funding

  • 2021 - 2025
    A practice change for patients with severe chronic, clinically unexplained gastrointestinal symptoms: A randomised, controlled intervention to assess efficacy and cost-effectiveness
    NHMRC IDEAS Grants
    Open grant
  • 2020 - 2024
    Modulation of the Gastrointestinal Microbiome with probiotics and subsequent Methane production as a novel approach to treat constipation: A Proof of Principle Study (TRI Sport Grant led by PAH)
    Metro South Hospital and Health Service
    Open grant
  • 2020 - 2025
    Targeting the gut microbiome as a treatment for Primary Sclerosing Cholangitis: The Queensland Clinical Network Study
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2019 - 2024
    Centre for Research Excellence in Digestive Health (NHMRC CRE administered by University of Newcastle)
    University of Newcastle
    Open grant
  • 2016
    Establishing a gnotobiotic germ-free mouse facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016
    The Australian human microbiota project-microbe isolation facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2015 - 2018
    Pathophysiology of functional dyspepsia: Integration of upper gut function, inflammation and a systems biology approach.
    NHMRC Project Grant
    Open grant
  • 2014 - 2017
    Functional dyspepsia: Characterisation of the immunopathology and testing a novel therapeutic strategy (NHMRC Project Grant administered by the University of Newcastle)
    University of Newcastle
    Open grant

Availability

Professor Gerald Holtmann is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    IBD and mental health tools: a holistic approach to discovery and appropriate tool.

    Principal Advisor

    Other advisors: Dr Ayesha Shah

  • Doctor Philosophy

    Effects the COVID-19 pandemic on the outcome and management of highly prevalent gastrointestinal conditions

    Principal Advisor

    Other advisors: Dr Ayesha Shah

  • Doctor Philosophy

    Exercise training on people with severe chronic, clinically unexplained gastrointestinal symptoms: A randomised, controlled trial.

    Associate Advisor

    Other advisors: Professor Jeff Coombes

  • Doctor Philosophy

    Targeting the gastrointestinal mucosa associated microbiome to improve clinical outcomes

    Associate Advisor

    Other advisors: Dr Ayesha Shah

  • Doctor Philosophy

    The role of the gut microbiome in alcohol related liver disease

    Associate Advisor

    Other advisors: Professor Jason Connor, Honorary Professor Paul Clark

  • Doctor Philosophy

    Study of TOfacitinib for the treatment of chronic Pouchitis

    Associate Advisor

    Other advisors: Associate Professor Jakob Begun

Completed supervision

Enquiries

Contact Professor Gerald Holtmann directly for media enquiries about:

  • colon cancer screening
  • Gastroenterology
  • Gut Health
  • Microbiome
  • Neurogastroenterology

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au